CJC-1295 DAC Research

What Is CJC-1295 DAC and How Does It Work?

CJC-1295 DAC (CJC-1295 with Drug Affinity Complex) is a modified synthetic analog of GHRH created through conjugation of a tetrapeptide-substituted GHRH analog to a proprietary drug affinity complex (DAC). This modification allows the peptide to bind endogenous albumin in circulation, dramatically extending its functional half-life from 30-45 minutes (unmodified GHRH) to approximately 6-8 days.

The mechanism of action remains GHRH-specific: it binds GHRH receptors on somatotroph cells in the anterior pituitary gland, stimulating growth hormone synthesis and secretion. Unlike GHRH without DAC (which produces pulsatile GH release), CJC-1295 DAC delivers sustained, near-continuous GH elevation due to its extended half-life and albumin binding, resulting in higher baseline GH levels with reduced pulse amplitude compared to native GHRH dynamics.

Clinical Trial Evidence: ConjuChem Phase I and Phase II Studies

CJC-1295 DAC was initially developed for therapeutic management of adult growth hormone deficiency (AGHD). The primary clinical evidence comes from Phase I and Phase II trials conducted by ConjuChem Biotechnologies, published in peer-reviewed literature including work by Teichman et al. (2006) in the Journal of Clinical Endocrinology & Metabolism.

Phase I Trial Design: Early studies assessed safety, pharmacokinetics, and dose-ranging in healthy subjects receiving single subcutaneous injections of CJC-1295 DAC at doses ranging from 3 to 30 µg/kg. Researchers measured GH levels, IGF-1 elevation, cortisol suppression, and adverse events over extended observation periods (24-48+ hours post-injection).

Key Phase I Findings: Single injections demonstrated dose-dependent GH elevation with peak plasma GH levels at 2-6 hours post-injection, followed by sustained elevation above baseline for 6-8 days. IGF-1 responses showed elevation within 24-48 hours, peaking around days 3-4 and remaining elevated for 7-14 days. Cortisol levels remained suppressed throughout the elevation period, indicating GHRH-mediated secretion. No serious adverse events were reported in Phase I.

Phase II Trial Design: Multiple-dose Phase II studies evaluated 12-16 week treatment periods with either weekly or twice-weekly CJC-1295 DAC injections (1-2 mg per injection) in subjects with AGHD or age-related growth hormone decline. These trials assessed body composition changes, muscle strength, metabolic markers, and safety.

Key Phase II Findings: Sustained weekly dosing produced cumulative IGF-1 elevation without progressive rise or tolerance development across the study period. Subjects demonstrated modest improvements in body composition metrics (increased lean mass, decreased fat mass) and modest strength gains. Sleep quality improved in subjective reports. Cardiovascular function remained stable as measured by echocardiography. One Phase II subject death occurred, attributed to pre-existing coronary artery disease unrelated to study drug.

GH Pulsatility and Sustained Elevation Dynamics

A critical distinction between CJC-1295 DAC and other GH secretagogues (such as GHRP-2/6) is the sustained elevation pattern versus native pulsatile release. Native GH secretion occurs in discrete pulses every 90-120 minutes, with most secretion occurring during slow-wave sleep. GHRH is the primary driver of these pulses.

CJC-1295 DAC eliminates this pulsatile pattern through continuous albumin-mediated GHRH receptor stimulation. This produces persistent baseline GH elevation (typically 3-5 ng/mL above baseline continuously) without the spike-and-trough pattern of native secretion. Pulsatile GH is considered more physiologically optimal for some metabolic outcomes (protein synthesis, fat mobilization), while sustained elevation produces greater cumulative IGF-1 increase and may better support anabolic signaling in some tissues.

Research suggests sustained GH elevation at moderate levels may support enhanced protein synthesis, improved glucose handling in early stages, and greater fat mobilization compared to pulsatile patterns—however, sustained elevated GH also increases carpal tunnel syndrome risk, water retention, and joint aches at higher doses, potentially explaining why some researchers favored CJC-1295 without DAC (shorter half-life, more pulsatile) for therapeutic applications.

IGF-1 Elevation Kinetics and Magnitude

CJC-1295 DAC's primary anabolic effect is mediated through IGF-1 elevation. Clinical trials demonstrated consistent IGF-1 responses following a predictable temporal pattern:

24-48 Hour Window: IGF-1 begins rising within 24 hours of injection as the liver responds to sustained GH elevation. Increases of 50-150 ng/mL above baseline are typical within this window.

Peak IGF-1 (Days 3-4): Maximum IGF-1 elevation typically occurs 3-4 days post-injection, with increases of 100-250 ng/mL above baseline in most subjects (absolute peak IGF-1 values of 250-400 ng/mL depending on baseline).

Sustained Plateau (Days 5-8): IGF-1 remains elevated above baseline through day 7-8, declining gradually as GH levels fall toward pre-injection baseline.

Weekly Dosing Accumulation: In weekly dosing protocols, successive injections produce cumulative IGF-1 elevation with minimal week-to-week fluctuation by week 3-4. Most subjects achieve plateau IGF-1 values 150-300 ng/mL above individual baseline within 4 weeks of weekly dosing.

This predictable IGF-1 kinetics supports consistent anabolic signaling and may explain subjective reports of improved recovery and body composition changes in clinical trial subjects, though magnitude was modest (typical body composition changes: 2-5 lb lean mass gain over 12-16 weeks).

Evidence Quality Assessment and Study Limitations

CJC-1295 DAC clinical evidence is limited primarily to Phase I and II trials. There are no published Phase III trials or long-term safety data beyond 16-24 weeks of continuous use. Evidence quality considerations:

Strengths: Peer-reviewed publication in high-impact journals; controlled, dose-ranging design in Phase I; multiweek duration with objective biomarker endpoints (GH, IGF-1, cortisol); safety monitoring including cardiovascular assessment; consistent findings across multiple subjects.

Limitations: Small subject numbers (typical Phase I/II: 20-50 subjects); limited diversity (primarily healthy adults or AGHD patients); no long-term (>16 weeks) data; no comparison groups receiving placebo in Phase II trials; one subject death (though deemed unrelated); development discontinued post-Phase II, limiting motivation for additional studies; very few published studies since 2006.

Evidence Rating: Moderate quality for acute GH/IGF-1 elevation (consistent findings, published data). Low quality for long-term safety or real-world efficacy, particularly in athletic or anti-aging contexts where data is entirely anecdotal.

Comparison with Other GH Secretagogues: Research Perspective

CJC-1295 DAC's clinical profile differs significantly from other GH-releasing agents studied in humans:

vs. GHRH (without DAC): GHRH alone requires multiple daily injections due to 30-45 minute half-life, whereas CJC-1295 DAC allows once- or twice-weekly dosing. Both produce similar GH secretion mechanisms (GHRH receptor activation), but CJC-1295 DAC's sustained elevation differs from GHRH's more pulsatile pattern.

vs. GHRPs (GHRP-2, GHRP-6): GHRPs work via distinct ghrelin-receptor pathways and require multiple daily doses. When combined with GHRH, GHRPs enhance GH release synergistically. Clinical data on GHRPs is similarly limited to small Phase I/II trials.

vs. MK-677 (Ibutamoren): MK-677 is a ghrelin mimetic available through pharmaceutical channels in some countries. It requires daily oral dosing versus weekly injection for CJC-1295 DAC. Clinical evidence on MK-677 is more robust (multiple trials published 2008-2018), showing similar body composition benefits with different safety profiles.

vs. Recombinant Human GH: Recombinant GH is FDA-approved for therapeutic AGHD but carries greater risk of adverse effects (carpal tunnel, arthralgia) at equivalent GH elevation levels, likely due to the non-physiologic continuous elevation. Clinical trials suggest CJC-1295 DAC produces more physiologic IGF-1 elevation with lower adverse event rates, though this comparison lacks head-to-head trials.

Current Research Status and Regulatory Path

CJC-1295 DAC development was discontinued by ConjuChem post-Phase II, meaning no Phase III efficacy trials were conducted and the compound never achieved FDA approval for any indication. The WADA (World Anti-Doping Agency) banned CJC-1295 DAC in 2008 as a prohibited GH secretagogue, classifying it in the same category as recombinant GH.

Currently, CJC-1295 DAC exists in a legal gray area: not FDA-approved, not available through licensed pharmaceutical channels in the US or most Western countries, but available through research chemical suppliers and marketed as "research peptide" or "not for human use." The scientific literature on CJC-1295 DAC has essentially stalled—no new published clinical trials have emerged since approximately 2008-2010.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

FAQ: CJC-1295 DAC Research Questions